19 citations
,
March 2018 in “JAMA” This guideline discusses the evaluation and treatment of hirsutism in premenopausal women, recommending oral contraceptive pills or antiandrogens as initial therapies with weak support from low-quality evidence.
117 citations
,
February 2017 in “American Journal of Clinical Dermatology” This systematic review concluded that the support for using spironolactone at commonly prescribed doses is based on evidence of limited quality.
75 citations
,
December 2011 in “British Journal of Dermatology” This review discusses female pattern hair loss, its psychological impact, and available treatments but provides no new clinical findings; the authors emphasize early intervention for better outcomes.
18 citations
,
June 2010 in “Current medicinal chemistry” This review discusses current treatment options for hirsutism, emphasizing the importance of combining therapies for better outcomes, but reports no new clinical findings.
November 2009 in “Cambridge University Press eBooks” This review discusses the necessity for hair transplant surgeons to be well-versed in both surgical and medical treatments for various forms of alopecia, and it reports no new results.
75 citations
,
November 2007 in “Clinical endocrinology” This study found that several drugs, including flutamide and spironolactone, significantly reduced hirsutism in women, with reduced effectiveness in those with higher BMI.
68 citations
,
May 1991 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.
19 citations
,
July 1990 in “Cleveland Clinic journal of medicine” This article reviews endocrine therapies for androgen excess disorders, emphasizing spironolactone, estrogen, and dexamethasone as effective treatments; it reports no new clinical results.
20 citations
,
May 1990 in “Cleveland Clinic journal of medicine” This study suggests spironolactone, particularly when combined with an oral contraceptive or dexamethasone, may reduce hair symptoms in women with hirsutism, but it should be avoided during pregnancy and in women with a family history of breast cancer.
39 citations
,
November 1978 in “Annals of internal medicine” This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.